Abbott Laboratories

NYSE ABT

Download Data

Abbott Laboratories Total Non-Current Liabilities 3 year CAGR for the quarter ending March 31, 2024: -9.91%

Abbott Laboratories Total Non-Current Liabilities 3 year CAGR is -9.91% for the quarter ending March 31, 2024, a -106.82% change year over year. Total Non-Current Liabilities is the sum of long-term debt and other non-current liabilities. CAGR, or the Compound Annual Growth Rate, quantifies the mean annual growth rate of an investment or financial metric over a specified time span, considering the influence of compounding. It is instrumental in determining the true annualized return on an investment.
  • Abbott Laboratories Total Non-Current Liabilities for the quarter ending March 31, 2023 was USD 22.04 B, a -14.33% change year over year.
  • Abbott Laboratories Total Non-Current Liabilities for the quarter ending March 31, 2022 was USD 25.73 B, a -3.03% change year over year.
  • Abbott Laboratories Total Non-Current Liabilities for the quarter ending March 31, 2021 was USD 26.54 B, a 3.89% change year over year.
  • Abbott Laboratories Total Non-Current Liabilities for the quarter ending March 31, 2020 was USD 25.54 B, a -6.67% change year over year.
NYSE: ABT

Abbott Laboratories

CEO Mr. Robert B. Ford
IPO Date Jan. 13, 1978
Location United States
Headquarters 100 Abbott Park Road, North Chicago, IL, United States, 60064-6400
Employees 114,000
Sector Healthcare
Industry Medical devices
Description

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. It also offers laboratory and transfusion medicine systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics polymerase chain reaction instrument systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, and detect and measure infectious agents; point of care systems; cartridges for testing blood gas, chemistry, electrolytes, coagulation, and immunoassay; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; drug and alcohol test, and remote patient monitoring and consumer self-test systems; and informatics and automation solutions for laboratories. In addition, the company provides pediatric and adult nutritional products; rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; diabetes care products, such as glucose and blood glucose monitoring systems; and neuromodulation devices for the management of chronic pain and movement disorders. Abbott Laboratories was founded in 1888 and is based in North Chicago, Illinois.

Similar companies

MDT

Medtronic PLC

NA

NA

StockViz Staff

September 19, 2024

Any question? Send us an email